A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension.
Badenhorst
D
D
Anamourlis
C
C
Gibbs
M
M
Maseko
M
M
Osadchii
O
O
Woodiwiss
A J
AJ
Norton
G R
GR
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D003094:Collagen / Q000032:analysis; D004108:Dilatation, Pathologic / Q000139:chemically induced / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004452:Echocardiography; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006973:Hypertension / Q000473:pathology* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000473:pathology* / Q000503:physiopathology; D007545:Isoproterenol / Q000494:pharmacology*; D009206:Myocardium / Q000737:chemistry; D010431:Pentoxifylline / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D014159:Transducers; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
D000318:Adrenergic beta-Agonists; D010726:Phosphodiesterase Inhibitors; D003094:Collagen; D007545:Isoproterenol; D010431:Pentoxifylline